Multiple myeloma · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Thalidomide monotherapy Variant #04 | — | R 8 341 | 28d | ~23.0 mo | — | ~2 | ~R 16 682 PFS proxy · indirect | 1 |
Lenalidomide and Dexamethasone (Rd) Variant #02 | — | R 4 309 | 28d | ~21.0 mo | ~55.4 mo | ~40 | ~R 132 764 PFS proxy · indirect | 26 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~41.0 mo | ~113.8 mo | ~24 | ~R 52 272 PFS proxy · indirect | 4 |
Melphalan and Prednisone (MP) Variant #18 | — | R 132 | 42d | — | ~29.1 mo | ~10 | ~R 1 102 PFS proxy · indirect | 2 |
Observation Partial | — | — | — | ~13.0 mo | — | — | — | 2 |
5 of 5 regimens shown